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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in South
East Asia. Although activation of the MEK-MAPK is often associated with cellular growth, the role
of MEK-MAPK in growth and survival of hepatocarcinoma cells has not been established.
Methods: Immuno-histochemistry was used to localize phosphorylated MAPK and MEK1/2 in the
tissues. 3-(4,5-Dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) assay and ELISA
were used to determine cell viability and cell proliferation. Deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) assay was used to detect apoptotic cells. Western blots analysis
was performed to determine the levels of proteins involved in the MEK-MAPK and apoptotic
pathways. Transfection study was performed to assess the role of MEK-MAPK pathway in growth
and survival of liver cancer cells.
Results: We report that phosphorylation of MEK1/2 at Ser217/221 was detected by immuno-
histochemistry in 100% (46 of 46) of HCCs examined. A positive signal was localized in the nuclei
of hepatocarcinoma cells but not in dysplastic hepatocytes or stromal cells. Over-expression and
phosphorylation of MAPK was also detected in 91% (42 of 46) and 69% (32 of 46) of HCCs
examined, respectively. The percentage of cells showing positively for phosphorylated MEK1/2
increased with advancing tumor stage. In vitro, treatment of human HepG2 and Hep3B cells with
MEK1/2 specific inhibitors U0126 and PD98059 led to growth inhibition and apoptosis. U0126
induced the release of cytochrome c and increased the cleavage of caspase-3, caspase-7, and poly
ADP-ribose polymerase (PARP). Inhibition of phosphatidylinositol 3-kinase (PI-3K), c-Jun N-
terminal kinase (JNK) and p38 kinase activities caused only a mild apoptosis in HepG2 and Hep3B
cells. Activated MEK1-transfected cells were more resistant to UO126-induced apoptosis in vitro
and formed larger tumors in SCID mice than mock-transfected cells.
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Conclusion: In conclusion, our results demonstrate that MEK-MAPK plays an important role in
the growth and survival of liver cancer cells and suggest that blocking MEK-MAPK activity may
represent an alternative approach for the treatment of liver cancer.
Background
HCC is one of the most common malignancies in South
East Asia. The incidence of HCC is between 250,000 to 1,2
million cases per year [1,2]. The disease is associated with
environmental exposure to hepatitis B virus, hepatitis C
virus, and Aflatoxin B1 [1,2]. Treatment outcomes for
HCC have remained generally poor. The majority of the
patients with HCC have inoperable disease with a very
poor prognosis [3]. Five-year survival rate is limited to 15
to 39% after surgery [4,5]. Long-term survival is uncom-
mon because of the frequency of recurrence in the form of
metastases or the development of new primaries [6,7].
There are also not currently accepted adjuvant or palliative
treatment modalities that have been conclusively shown
to prolong survival in HCC [8].
Several lines of evidence indicate that HCC may be the
result of inactivation of tumor suppressor genes, activa-
tion of multiple oncogenes and over-expression of growth
factors. More than 20 cellular genes have been identified
to be associated with HCC (Reviewed in [9]). They
include Ras, c-myc, c-fos and c-jun, rho, transforming
growth factor-α, hepatocyte growth factor and c-met, c-
ErbB-2, u-plasminogen activator, MXR7, MDM2, MAGE,
matrix metalloproteinase, Smads, p53, pRB, p16INK4,
p21WAF1/CIP1, p27Kip1, PTEN, E-cadherin, β-catenin, AXIN1
and HCCA1. We recently reported [10] that insulin-like
growth factor (IGF) II (IGF-II) is over-expressed in approx-
imately 39% of HCC samples. In addition, IGF binding
protein 3 (IGFBP-3) is either undetectable (28.5%) or low
(71.5%) in HCCs examined compared with adjacent
benign liver (ABL) tissues.
One of the most frequent targets downstream of receptor
and non-receptor tyrosine kinases and the ras family of
GTP-binding proteins is the MEK-MAPK signal transduc-
tion pathway [11,12]. Elevated levels of constitutively
activated MEK1 are seen frequently in carcinoma cell lines
[13,14]. Constitutive MEK1 activation contributes to cell
survival (Reviewed in [12]), migration [15], transforma-
tion of fibroblasts and epithelial cells [16-18]. Studies
with small molecule inhibitors of MEK activity [19,20].
demonstrate a role for MEK in mediating expression of
proteinases implicated in invasion and metastasis
[21,22], and disruption of normal epithelial morphology
[23,24]Treatment of HepG2 with PD98059 resulted in
apoptosis [25]. No substrates of MEK have been identified
other than p44/42 MAPK (Reviewed in [26]). Increased
MAPK (ERK1/2) and MEK1/2 expression and p42 MAPK
in 5 HCC samples has been reported [27]. Treatment of
cells with various growth factors produces activation of
MEK1/2 and its downstream target, MAPK, resulting in
proliferation, differentiation and survival
(Reviewed in [12]). Activation of MAPK regulates the
activities of a number of substrates including transcription
factor p62TCF (Elk-1), c-myc, ATF2 and AP-1 components,
c-Jun and c-fos [20]. MAPK is also involved in nuclear
transport, nucleosome assembly, and cytoskeletal regula-
tion [28]. The tight selectivity of MEK1/2, coupled with its
unique ability to phosphorylate both tyrosine and threo-
nine residues of MAPK, indicates that this kinase is essen-
tial in integrating signals into the MAPK pathway. Thus,
MEK1/2 represents an excellent target for pharmacologi-
cal intervention in proliferative disease [19,29,30]. Sev-
eral MEK-MAPK anticancer drugs are currently in clinical
trials [31].
In this study, we report that the protein MEK1/2 is acti-
vated in 100% of HCCs examined. Tumor cells were the
main sites of activated MEK1/2 and MAPK proteins within
HCCs and not the surrounding non-neoplastic tissues.
Over-expression and hyperphosphorylation of MAPK
were detected in 91% and 69% of HCCs examined,
respectively. Treatment of HepG2 and Hep3B cells with
U0126 led to a time and dose-dependent reduction in cell
proliferation and apoptosis. Over-expression of activated
MEK1 in HepG2 enhanced tumor growth in vivo and con-
ferred resistance to U0126-induced apoptosis in vitro. Our
data suggest that blocking MEK-MAPK activities may rep-
resent a novel approach for the treatment of HCC.
Experimental Procedures
Reagents
U0126, PD98059 and LY294002 were supplied by New
England Biolabs, Beverly, MA. p38 kinase inhibitor
SB203580 and JNK inhibitor SP600125 were purchased
from Calbiochem, San Diego, CA. They were dissolved in
dimethylsulfoxide (DMSO) with the final concentration
of 20 mM and stored frozen under light-protected condi-
tions at -20°C. Antibodies against α-tubulin, rabbit anti-
p38 kinase, rabbit anti-phospho-p38 kinase (Tyr182),
rabbit anti-JNK-2, rabbit anti-phospho-JNK (Thr183/
Tyr185), mouse anti-cytochrome c, mouse anti-MAPK,
rabbit anti-Akt-1 and MEK-1 were obtained from Santa
Cruz Biotechnology, Santa Cruz, CA. Anti-cleaved form-
specific caspase-7 (20 kDa), caspase-3 and caspase-9, rab-
bit anti-phospho Akt-1 (Ser473), phospho-specific anti-BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/19
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MEK1/2 (Ser217/221), phospho-specific anti-MAPK
(Thr202/Tyr204), and cleaved PARP (89 kDa) antibodies
were obtained from Cell Signaling Technology, Beverly,
MA. Horseradish peroxidase-conjugated secondary anti-
bodies were supplied by Pierce, Rockford, Illinois. The
chemiluminescent detection system was supplied by
Amersham, Pharmacia Biotech, Arlington Heights, IL. 96-
well plates, tissue culture petri-dishes and 8-chamber
slides were from Nunc Inc., Naperville, IL. Cell Prolifera-
tion ELISA, BrdU (colorimetric), In Situ Cell Death Detec-
tion Kit and Fluorescein were supplied by Roche
Diagnostics Corporation, Indianapolis, IN.
Patients and tissue samples
Prior written informed consent was obtained from all
patients and the study received ethics board approval at
the National Cancer Centre of Singapore as well as the
Singapore General Hospital. Tissue samples were
obtained intra-operatively from tumors and ABL tissues
during liver resection for HCC in 46 patients at the Singa-
pore General Hospital. 14 of 46 resected samples had sin-
gle tumor and 32 of 46 had two tumors. The samples were
snap frozen in liquid nitrogen and stored at -80°C until
analysis. A similar set of samples was fixed in 10% forma-
lin and paraffin embedded. The diagnosis of HCC was
confirmed histologically in all cases.
Staging of tumors was performed using the TNM system
[32]. In addition, every tumor was examined macroscopi-
cally and microscopically for capsule formation, satellite
nodules, multiplicity and necrosis. Dysplasia and cirrho-
sis in the surrounding liver tissue were noted. 15 of 46
tumors were associated with cirrhosis. Within 15 cirrhotic
HCCs, 12 showed dysplastic changes in adjacent non-
neoplastic tissue. Multifocality was defined as multiple
small uniformly sized tumors that likely represented inde-
pendent primary tumors [33]. This is distinguished from
satellites, which were defined as tumor nodules, smaller
than the main tumor mass, located within a maximum
distance of 2 cm. The term multiplicity was used for both
multifocal tumors and for multiple intrahepatic metasta-
sis from a single primary tumor that were situated further
than 2 cm from the edge of the main tumor mass.
Immunohistochemical analysis and assessment
For immunohistochemical analysis of MEK1/2 and MAPK
or Ki-67, sections (5 µM thick) were cut, dewaxed, rehy-
drated and antigen retrieval as described [10]. After block-
ing endogenous peroxidase activity and reducing
nonspecific background staining, the sections were incu-
bated with the primary antisera against phosphorylated
MEK1/2 (Ser217/221) or phosphorylated MAPK
(Thr202/Tyr204) (overnight at 4°C). Immunohistochem-
istry was performed using the streptavidin-biotin peroxi-
dase complex method, according to the manufacturer's
instructions (Lab Vision, Fremont, CA) using AEC as the
chromogen. Sections known to stain positively were incu-
bated in each batch and negative controls were also pre-
pared by replacing primary antibody with preimmune
sera. Only nuclear immunoreactivity was considered pos-
itive. For phosphorylated MEK1/2, tumors were scored as
1 (<1.0% of tumor cells positive); 2 (1–5% of tumor cells
positive); 3 (5–10% of tumor cells positive) and 4 (>10%
of tumor cells positive). To determine the rate of cellular
proliferation in vivo, sections derived from tumor
xenografts of mock-transfected and activated MEK1-tran-
fected HepG2 cells were stained with anti-Ki-67 antibody.
Five hundred tumor cells were counted in randomly cho-
sen fields at ×400 magnification. The Ki-67 labelling
index was expressed as the number of clearly labelled Ki-
67 reactive nuclei in 500 cells counted.
Cell viability and cell proliferation
Human hepatoma HepG2 and Hep3B cells were obtained
from American Type Culture Collection (Rockville, Mary-
land) and maintained as monolayer cultures in Modified
Eagle's Media (MEM) supplemented with 10% fetal
bovine serum (growth medium). For study of prolifera-
tion, confluent cultures of cells were trypsinized and
plated at a density of 2.0 × 104 cells in 24-well plates with
growth medium. After 48 h, the cell monolayer was rinsed
twice with phenol-red-free-serum-free MEM (PSF)
medium and incubated further in PSF medium for 24 h.
After 24 h, various concentrations of U0126 (0, 2, 4, 6, 8
and 10 µM) or 10 µM LY294002 or 50 µM PD98059 or 5
µM SB203580 or 10 µM SP600125 in PSF medium were
added and incubated for 24 h or 48 h. Cell viability and
cell proliferation were determined by the MTT assay [34]
and Cell Proliferation ELISA, Bromo-deoxyuridine (BrdU)
kit (Roche) respectively as described by the manufacturer.
Experiments were repeated at least 3 times, and the data
were expressed as the mean ± SE.
Detection of apoptotic cells
HepG2 and Hep3B cells were grown in 8-chamber slides
and treated with appropriate concentrations of U0126 in
PSF medium for 48 h. Cells were fixed with phosphate
buffer saline (PBS) containing 4% formalin solution for 1
hour at room temperature and washed with PBS. Apopto-
sis was detected by TUNEL assay using the In Situ Cell
Death Detection Kit (Roche) as described by the manufac-
turer. Apoptotic cells were then visualized under fluores-
cent microscope equipped with an FITC filter. Labelling
indices were obtained by counting cell number of labelled
cells among at least 500 cells per region and expressed as
a percentage values.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/19
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Preparation of mitochondria-free cytosol for detection of 
cytochrome c release
HepG2 or Hep3B were grown in the presence of indicated
concentrations of U0126 or PD98059 or SB203580 or
SP600125 in PSF medium for 24 h or 48 h. Cells were har-
vested, washed with ice-cold PBS. Mitochondria-free
cytosol was prepared as described [35]. For detection of
cytochrome c release, mitochondria-free cytosol was ana-
lyzed by Western blot analysis as described [10].
Western Blotting
Tissue lysates from HCCs and ABL tissues as well as cell
lysate were prepared as previously described [10]. Tissue
or cell lysate or mitochondria-free cytosol was subjected
to Western blot analysis as previously described [10].
Blots were incubated with indicated primary antibodies
and 1:7500 horseradish peroxidase-conjugated secondary
antibodies. The blots were then visualized with a chemi-
luminescent detection system (Amersham) as described
by the manufacturer.
Stable activated MEK1 cell lines
To examine whether activated MEK was associated with
the growth and survival of liver cancer cells, HepG2 cells
were transfected with 5 µg of the pUSE-MEK1 (S218D/
S222D) or pUSE control plasmid DNA and 28 µl of Lipo-
fectamine reagent (Life Technologies) following the man-
ufacturer's recommendation. The pUSE-MEK1 (S218D/
S222D) was the Ha-Tagged rat MEK1 (activated) cDNA
(Upstate, Lake Placid, NY). The activating mutations were
the substitutions of aspartic acid for serine at residues 218
and 222. Forty-eight hours post-transfection, cells were
subcultured at a ratio of 1:10 and replaced with selective
growth medium containing 800 µg/ml G418 (Calbio-
chem, La Jolla, CA). Four weeks post-transfection, individ-
ual clones were isolated, expanded and assayed for MEK1
expression by Western blot analysis using anti-HA tag
antibody (1:1000 dilution). The phenotype of transfect-
ants expressing activated MEK1 was compared with that of
control pUSE plasmid. The proliferative behaviour of the
clones and in vivo tumor formation were assayed.
For proliferation study, 2.5 × 104 cells were seeded per
well in 24-well plates containing MEM supplemented
with 10% fetal bovine serum. Cell number was counted
daily by hemocytometer for 5 days. Means were deter-
mined from quadruplicate wells and in no case did stand-
ard deviation exceed 15% of the mean value.
Tumorigenicity in SCID mice
Male SCID mice of 9–10 weeks of age were purchased
from the Animal Resources Centre, Canning Vale, West
Australia. All mice were maintained according to the
"Guide for the Care and Use of Laboratory Animals" pub-
lished by National Institute of Health, USA. They were
provided with sterilized food and water ad libitum, and
housed in negative pressure isolators with 12 h light/dark
cycles. 5 × 106 cells (2 mock-transfected clones, pUSE-9
and pUSE-12; and 2 activated MEK1-transfected clones,
H-MEK1-15 and H-MEK1-17) were suspended in calcium
free phosphate buffer saline and subcutaneously injected
on both sides of the SCID mice. Tumor growth was mon-
itored at least twice weekly by vernier caliper measure-
ment of the length (a) and width (b) of tumor. Tumor
volumes was calculated as (a × b2)/2. Eight animals per
group were used in three sets of independent experiments.
All mice were sacrificed when the tumors reached approx-
imately 1 cm3. Tumors were harvested, fixed and paraffin
embedded for determination of apoptosis and prolifera-
tion. Differences in tumor incidence number and tumor
volume among groups were analyzed by ANOVA.
Statistical analysis
For quantitation analysis, the sum of the density of bands
corresponding to protein blotting with the antibody
under study was calculated, and the amount of α-tubulin
normalized. For MAPK, phosphorylated MAPK, MEK1/2
and phosphorylated MEK1/2, the mean of densitometric
scanning in the adjacent benign tissues and tumors was
determined. To estimate the specific increase in MEK or
MAPK phosphorylation, the ratio of pMEK1/2/ MEK and
pMAPK/MAPK was calculated. Differences in cell number
and the levels of protein under study were analyzed by
ANOVA.
Results
Pathologic evaluation of the resected specimens showed
cirrhosis without dysplasia (3 of 46) and with dysplasia
(12 of 46) in adjacent non-neoplastic liver in 33% (15 of
46) patients. Multiplicity of tumors was detected in 32
cases (70%) with 2 or 3 HCC nodules. Satellite formation
occurred in 26 (56%) patients. The overall observed 1-
year disease-free survival rate of all patients was 74% (34
of 46). In this study, the median survival of all HCC
patients studied and the 5-year survival rate was not
calculated.
Since the MEK-MAPK pathway has been implicated in reg-
ulating cell growth and survival (Reviewed in [12]), the
abundance of MAPK was determined in HCCs and ABL
tissues. Figure 1 shows that the 42 and 44 kDa forms of
MAPK were detected in both HCCs and ABL tissues. Eleva-
tion of MAPK was detected in 91% (42 of 46) of HCCs
examined. Quantitative analysis revealed that HCCs had
approximately 1.6-fold more MAPK than ABL tissues.
When the blots were stripped and reblotted with anti-
phosphorylated MAPK (active form of MAPK), 69% (32
of 46) of HCCs displayed increased staining as compared
with ABL tissues (Fig. 1A, 1B &1C). The ratio of pMAPK/BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/19
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MAPK protein and phosphorylated MAPK were markedly elevated in extract of HCCs as compared with ABL tissues Figure 1
MAPK protein and phosphorylated MAPK were markedly elevated in extract of HCCs as compared with ABL 
tissues. Human HCCs (T) and ABL tissues (N) were collected and tissue lysate was prepared as described under Experimen-
tal Procedures. Samples (100 µg protein/sample) were subjected to Western blot analysis as described [10]. Blots were incu-
bated with mouse anti-MAPK and mouse anti-phospho-MAP kinase (Thr202/Tyr204) (A, B and C) (A, B and C) and mouse 
anti-α-tubulin antibodies. The ratio of phosphorylated MAPK to MAPK is shown in (D). Bars with different letters are signifi-
cantly different from one another at p < 0.01 as determined by ANOVA test. All the samples in A &B are paired and samples 
in C are individual.
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MAPK was significantly higher (p < 0.01) in HCCs as com-
pared to ABL tissues as determined by ANOVA (Fig. 1D).
Since increased MAPK phosphorylation may reflect activa-
tion of MAPK via upstream signalling elements, the
amount of phospho MEK1/2 was determined in tissue
extracts from both HCCs and ABL tissues. Immunostain-
ing of the blots displayed a marked increase in phosphor-
ylated MEK1/2 (Fig. 2A, 2B &2C). While MEK 1/2 was
heavily phosphorylated on serine 217/221 in 100% (46/
46) of HCCs, ABL tissues of the same patients showed lit-
tle phosphorylated MEK1/2 under the same conditions
(Fig. 2A, 2B &2C). Approximately 7-fold increase in
MEK1/2 phosphorylation was detected in HCC as com-
pared with ABL tissues (Fig. 2D).
HCC tumors are heterogeneous with respect to cell-type,
and therefore it was critical to identify the cell-type
responsible for the elevation of phosphorylated MEK1/2
and MAPK. A total of 46 HCCs and their ABL tissues were
examined by immunohistochemistry. An antibody spe-
cific for phosphorylated MEK1/2 at serine (Ser217/221)
was used to stain the tissue sections. Figure 3A and 3B
show that intense staining was observed only in the nuclei
of cancerous hepatocytes, some of which underwent
mitotic division. No nuclear staining was observed in
adjacent benign hepatocytes (Fig. 3A &3B). Bile duct epi-
thelial cells were uniformly negative, as were the fibrovas-
cular stroma within cirrhotic livers. A summary of the
immunohistochemical analysis of MEK1/2 phosphoryla-
tion in human HCCs is shown in table 1. The percentage
of cells showing positively for phosphorylated MEK1/2
appears to increase with advancing tumor stage. When the
above tissues were stained using phosphorylated MAPK at
threonine 202 and tyrosine 204, a strong immunoreactiv-
ity of the tumor cells was observed in tumor nodules (Fig.
3C &3D). Surrounding benign hepatocytes were weakly
positive for phosphorylated MAPK (Fig. 3C &3D).
The immunohistochemistry and Western blot analysis of
HCC samples suggested an important link between HCC
and activation of the MEK-MAPK pathway. However, the
role of MEK-MAPK activation in hepatogenesis and sur-
vival of hepatoma cells was not well understood. It has
been shown that MEK-MAPK activation generally plays a
critical role in cell proliferation and apoptosis (Reviewed
in [12]). It was reasoned that MEK-MAPK activation in
HCCs might enhance tumor cell proliferation and sur-
vival. To elucidate the role of MEK1/2 activation in the
growth and survival of hepatocarcinoma cells, we chal-
lenged human HepG2 cells with either vehicle or 10 µM
of highly selective MEK1/2 inhibitor U0126 or 50 µM of
PD98059. To serve as controls, HepG2 cells were also
treated with 5 µM of p38 kinase inhibitor SB203580 or 10
µM of JNK inhibitor SP600125 or 10 µM of PI-3 kinase
inhibitor LY294002. Figure 4 demonstrates that U0126
and PD98059 inhibited phosphorylation of MAPK while
SB203580, SP600125 and LY294002 effectively blocked
phosphorylation of p38 kinase and JNK and Akt-1 respec-
tively (Fig. 4A). While SB203580, SP600125 and
LY294002 had a little effect on cell viability as determined
by the MTT assay, both U0126 and PD98059 significantly
decreased the cell viability in HepG2 cells (Fig. 4B). Simi-
lar effects were observed when Hep3B were used (data not
shown).
Because HepG2 and Hep3B cells responded similarly to
U0126 or PD98059, subsequent experiments were mainly
performed on HepG2 cells. For the time-course and dose-
response experiments, HepG2 cells were treated with 0, 2,
4, 6, 8 and 10 µM U0126 in serum free medium for 24 h
and 48 h. Cell viability and cell growth were then assessed
by the MTT assay and BrdU incorporation, respectively.
Figure 5 shows that U0126 caused a dose-dependent
reduction in cell growth and viability. Significant inhibi-
tion in cell viability was observed as early as 24 hours
post-treatment. The effects were more pronounced and
dose-dependent at 48 h of treatment (Fig. 5B). Fifty-per-
cent inhibitions in cell growth and viability were detected
at a dose of 4 µM U0126. The influence of U0126 on cell
growth and viability occurred at the dose expected to sup-
press phosphorylation of MAPK (Fig. 8). Another
hepatoma cell line of human origin PLC/PRF/S was also
inhibited by U0126 treatment in a similar manner (data
not shown).
Phase-contrast photomicrographs revealed that U0126-
treated HepG2 cells displayed typical features of apopto-
sis: shrinkage of cytoplasm and membrane blebbing (Fig.
6). To assess if the cell death observed above represented
apoptosis, TUNEL assay was performed. While LY294002,
SB203580 and SP600125 caused a little cell death (data
not shown), U0126 induced apoptosis in a dose-depend-
ent manner (Fig. 7 &8B).
Since cytochrome c release plays a major role in mediating
apoptosis in several experimental systems [36-38], we
determined whether U0126-induced apoptosis in HepG2
cells was associated with cytochrome c release in the cyto-
plasm. Figures 4 shows that levels of cytochrome c in the
cytoplasm of HepG2 cells were significantly increased fol-
lowing U0126 or PD98059 treatment. Since the proteo-
lytic cleavage of caspase-3 and caspase-7 plays a central
role in PARP cleavage during apoptosis [39], we investi-
gated whether this apoptosis machinery was activated
upon U0126 or PD98059 treatment. The activation of
these two caspases and cleaved PARP were determined by
Western blot analysis using antibodies capable of detect-
ing cleaved caspase-3, caspase-7 and PARP. Cleaved cas-
pase-7 and cleaved caspase-3 fragments were detectable atBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/19
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Phosphorylated MEK1/2 was elevated in extract of HCCs as compared with ABL tissues Figure 2
Phosphorylated MEK1/2 was elevated in extract of HCCs as compared with ABL tissues. Human HCCs (T) and 
ABL tissues (N) were collected and tissue lysate was prepared as described in Experimental Procedures. Samples (100 µg pro-
tein/sample) were subjected to Western blot analysis as described [10]. Blots were incubated with rabbit anti-phospho-MEK1/
2 (Ser217/221), mouse anti-α-tubulin and rabbit anti-MEK1 antibodies (A, B and C). The ratio of phosphorylated MEK1/2 to 
total MEK is shown in (D). Bars with different letters are significantly different from one another at p < 0.01 as determined by 
ANOVA test. All the samples in A &B are paired and samples in C are individual.
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24 and 48 hours of U0126 treatment and increased in a
dose-dependent manner (Fig. 8A). The cleaved caspase-7
and -3 were detected at similar time course as PARP cleav-
age (Fig. 8A). In contrast, blocking PI-3 kinase, p38 kinase
and JNK activities by LY294002, SB20358 and SP600125
respectively abolished the phosphorylation of Akt-1, p38
kinase and JNK without affecting the levels of cleaved cas-
pase-3 and -7 (Fig. 4A). Furthermore, the levels of cyto-
chrome c released from mitochondria and PARP cleavage
were only slightly elevated following LY294002 or
SB20358 or SP600125 treatment (Fig. 4A) indicating that
MEK-MAPK but not PI-3 kinase or p38 or JNK plays a crit-
ical role in HepG2 cell survival under serum deprivation.
Since our in vitro study indicated that MEK1/2 activity was
required for the survival of liver cancer cells, transfection
studies were performed to determine whether over-
expression of MEK-MAPK would protect cells from
U0126-induced apoptosis and enhance tumor growth in
vivo. HepG2 cells were transfected with Ha-Tagged rat
MEK1 (activated) cDNA. The activating mutations were
the substitutions of aspartic acid for serine at residues 218
and 222. As shown in figure 9B, HA-MEK1 expression was
detected in representative transfected clones (H-MEK1-5,
H-MEK1-15, H-MEK1-16 and H-MEK1-17). Basal levels
of phosphorylated MAPK were also higher in activated
MEK1-transfected clones compared with mock pUSE-
transfected clones, pUSE-9 and pUSE-12 (Fig 9D). Since
Immunohistochemical demonstration of phosphorylated MEK1/2 and MAPK in malignant and adjacent benign hepatocytes Figure 3
Immunohistochemical demonstration of phosphorylated MEK1/2 and MAPK in malignant and adjacent benign 
hepatocytes. Human HCCs (T) and ABL tissues (N) were collected and paraffin blocks were prepared as described under 
Experimental Procedures. 5 µm sections were subjected to immunohistochemical analysis as described under Experimental 
Procedures. The sections were stained with primary antibody to phospho-MEK1/2 (Ser217/221) (A &B) or mouse anti-phos-
pho-MAP kinase (Thr202/Tyr204) (C &D) antibodies. Original magnification ×400.
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the MEK-MAPK pathway has been implicated in regulat-
ing cell growth (Reviewed in [12]), the proliferative
behavior of H-MEK1-15, H-MEK1-17, pUSE-9 and pUSE-
12 clones was evaluated by determining cell number on
plastic dishes daily for 5 days. As shown in figure 9E, there
was no significant increase in cell number in activated
MEK1-transfectant cells compared with mock-transfected
cells. The results suggest that over-expression of activated
MEK1 did not alter growth rate of HepG2 cells in culture.
Since constitutive MEK1 activation contributes to cell sur-
vival (Reviewed in [12]), we wished to determine if con-
stitutive activation of MEK-MAPK in HepG2 cells would
make the cells more resistant to U0126-induced apopto-
sis. Mock-transfectant pUSE-9 and activated MEK1-15
clones were selected for this study. They were treated with
0, 2, 4, 6 and 8 µM U0126 for 24 h. Because cleaved cas-
pase-3 and -7 and PARP has been proposed as one of the
events in the execution phase of apoptosis, the levels of
cleaved caspase-3, -7 and PARP were used as markers for
apoptosis. As shown in figures 10, cleaved caspase-3, -7
and PARP were readily detected in pUSE-9 cells at a dose
as low as 4 µM. In contrast, these apoptotic markers were
not detected in the H-MEK-15 cells at low doses of U0126.
They became visible only at a dose of 8 µM. Similar results
were obtained when the H-MEK1-17 clone was used (data
not shown). These results further supported the important
role of activated MEK-MAPK in the survival of liver cancer
cells.
To test the neoplastic behaviour of activated MEK1 cells in
vivo, mock-transfected pUSE-9 and pUSE-12 and activated
MEK1-transfected pMEK1-15 and pMEK1-17 clones were
injected in the flanks of SCID mice. Tumor formation was
detected in 40–45 and 55–60 days for activated MEK1-
transfected (H-MEK-15, H-MEK-17) and mock-trans-
fected (pUSE-9, pUSE-12) clones respectively. By day 60,
tumor incidence was 100% in both mock-transfected
clones (pUSE-9 and pUSE-12) and two activated MEK1
clones (H-MEK1-15 and H-MEK1-17). However, both the
H-MEK1-15 and H-MEK1-17 clones grew much faster
than the pUSE-9 and pUSE-12 clones (Fig. 11). The final
tumor volume was 270 ± 30 mm3 and 309 ± 25 mm3 for
pUSE-9 and pUSE-12 mock transfected clones respectively
and 1,210 ± 49 mm3 and 1,034 ± 54 mm3 for H-MEK1-15
and H-MEK1-17 clones respectively. Differences in tumor
volume between mock-transfected and activated MEK1-
transfected clones were statistically significant at p < 0.01
as analyzed in the ANOVA-test. To determine whether the
increased growth rate of HepG2-MEK1 tumors was due to
increase in cell proliferation, Ki-67 labelling index was
performed. As shown in figure 12, the Ki-67 labelling
index was slightly but significantly higher in HepG2-MEK-
1 than HepG2-mock tumors (p < 0.05). The results sug-
gest that over-expression of activated MEK1 enhances the
survival and to a lesser extent, the proliferation of HepG2
cells in vivo.
Discussion
Molecular genetic and biochemical studies of HCC have
revealed abundant evidence for aberrant growth factor
Table 1: A summary of immunohistochemical analysis of MEK1/2 and its phosphorylation at Ser217/221 in human HCC. Human HCCs 
(T) and adjacent benign liver (ABL) tissues (N) were collected, paraffin blocks were prepared and immunohistochemical analysis was 
performed as described under Experimental Procedures. Tissue sections were stained with anti-phospho-MEK1/2 (Ser217/221) 
antibody. Only nuclear immunoreactivity was considered positive. Sections were scored as 1 (<1.0% of tumor cells positive); 2 (1–5% of 
tumor cells positive); 3 (5–10% of tumor cells positive) and 4 (>10% of tumor cells positive).
Genes examined Normal adjacent Liver 
tissues (n = 46)
HCC Tumours (n = 46)
Stages
II I I I I I V
(n = 4) (n = 25) (n = 11) (n = 6)
MEK 1/2 46/46 (100%) 4/4 (100%) 25/25 (100%) 11/11 (100%) 6/6 (100%)
Phosphorylated MEK 1/2 Score 
(% of positive cells)
0/0 (0%)
1 (< 1.0) 0 2/4 (50%) 20/25 (80%) 4/11 (36.36%) 1/6 (16.67%)
2 (1 – 5) 0 - 4/25 (16%) 4/11 (36/36%) -
3 (5 – 10) 0 1/4 (25%) 1/25 (4%) 1/11 (9.09%) 3/6 (50%)
4 (>10) 0 1/4 (25%) - 2/11 (18.19%) 2/6 (33.33%)BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/19
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Effects of MEK1/2 inhibitor U0126 or PD98059, p38 kinase inhibitor SB203580, JNK inhibitor SP600125 and PI-3 kinase inhibi- tor LY294002 on cell viability, MAPK, Akt-1, phosphorylation of MAPK (Thr202/Tyr204), phosphorylation of Akt-1 (Ser473),  p38 kinase, phosphorylation of p38 kinase (Tyr182), JNK, phosphorylation of JNK (Thr183/Tyr185), cytochrome c release, and  cleavage of caspase 3, caspase 7 and PARP in HepG2 cells Figure 4
Effects of MEK1/2 inhibitor U0126 or PD98059, p38 kinase inhibitor SB203580, JNK inhibitor SP600125 and PI-
3 kinase inhibitor LY294002 on cell viability, MAPK, Akt-1, phosphorylation of MAPK (Thr202/Tyr204), phos-
phorylation of Akt-1 (Ser473), p38 kinase, phosphorylation of p38 kinase (Tyr182), JNK, phosphorylation of 
JNK (Thr183/Tyr185), cytochrome c release, and cleavage of caspase 3, caspase 7 and PARP in HepG2 cells. 
Cells were grown and treated with 0.1% of DMSO (C) or 10 µM of U0126 (U0) or 10 µM of LY294002 (LY) or 50 µM of 
PD98059 (PD) or 5 µM of SB203580 (SB) or 10 µM of SP600125 (SP) in phenol red free serum free MEM (PSF) medium for 
48 h as described under Experimental Procedures. Total cell lysate (for detection of all proteins except cytochrome c) or 
mitochondria free cytosol (detection of cytochrome c) from HepG2 (A) cells was subjected to Western blot analysis as 
described under Experimental Procedures. Blots containing total cell lysate were incubated with mouse anti-α-tubulin, mouse 
anti-phospho-MAPK (Thr202/Tyr204), rabbit anti-Akt-1, rabbit anti-phospho Akt-1 (Ser473), rabbit anti-p38, rabbit anti-phos-
pho-p38 (Tyr182), rabbit anti-JNK1/2, rabbit anti-phospho-JNK1/2 (Thr183/Tyr185), rabbit anti-caspase-3, rabbit anti-cleaved 
caspase-7 (20 kDa), rabbit anti-cleaved PARP antibodies. Blots containing mitochondria free cytosol were blotted with mouse 
anti-cytochrome c antibody. All the antibodies were used at a final concentration of 1 µg per ml. (B) Cell viability of HepG2 
following different treatments was analyzed by MTT assay as described under Experimental Procedures. Bars with different let-
ters are significantly different from one another at (p < 0.01) as determined by ANOVA test. The results represent the mean 
of 3 experiments ± SE is shown.
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Effects of U0126 on HepG2 cell viability and proliferation Figure 5
Effects of U0126 on HepG2 cell viability and proliferation. HepG2 cells were grown and treated with 0.1% DMSO or 
escalating doses of U0126 in PSF medium. Cell proliferation and cell viability were determined by BrdU incorporation and MTT 
assay, respectively as described under Experimental Procedures. HepG2 cell proliferation at 48-h (A) and cell viability at 24 and 
48 h (B) are shown. Experiments were performed in quadruplicate, with the results reflecting the mean of the quadruplicate of 
each group. Bars with different letters are significantly different from one another at (p < 0.01) as determined by ANOVA test. 
The results represent the mean of 3 experiments ± SE is shown.
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signalling, thus implicating downstream signalling path-
ways in HCC pathogenesis. Immunohistochemical appli-
cation of a phospho-state specific antibody MEK1/2 and
MAPK enables the morphological imaging of dynamic
intratumor signalling events. Using phospho-specific
MEK1/2 antibody we demonstrate significant activation
of MEK1/2 in 100% (46 of 46) of HCC tumors at both
early and late stages of malignancy. Only tumor cells
exhibit elevated MEK1/2 phosphorylation. Consistent
patterns of selective activation in tumor cells suggest that
activation of MEK1/2 may contribute to the neoplastic
liver phenotype. This in vivo analysis of active MEK1/2 and
MAPK in human HCCs, reported herein, reveals sharply
elevated activities of these proteins. The activation of
MAPK observed in HCCs could not be ascribed solely to
phosphorylation of the protein. Immunoblotting reveals
a marked increase in the amount of MAPK in 91% (42 of
46) of HCCs when compared with adjacent benign liver
tissues. The results are consistent with an early observa-
tion by Schmidt et al. [27] who demonstrated that MAPK
expression and p42 MAPK activity were significantly
higher in 5 HCCs examined as compared with 5 adjacent
normal control tissues. Treatment of human liver cancer
cells with MEK1/2 inhibitor U0126 or PD98059, which
inhibits MEK-MAPK activation, leads to a time- and dose-
dependent reduction in cell proliferation and viability.
Our data are in agreement with previous study [25] show-
ing that in vitro treatment of HepG2 with MEK inhibitor
PD98059 resulted in apoptosis. Furthermore, over-expres-
sion of activated MEK1 in HepG2 enhances tumor growth
Effects of U0126 on HepG2 cell morphology Figure 6
Effects of U0126 on HepG2 cell morphology. HepG2 cells were grown and treated with either 0.1% DMSO or 3 doses 
of U0126 in PSF medium for 48 h as described under Experimental Procedures. Bright field views of cells treated with 0.1% 
DMSO (A) or 2 (B), 4 (C), and 6 (D) µM of U0126 for 48 hours. Representative samples are shown. Original magnification, 
×200.
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in vivo and confers resistance to U0126-induced apoptosis
implicating the requirement of MEK-MAPK activity for
liver cancer cells to survive and tumor growth in vivo.
Although the etiology and pathogenesis of HCC remain
unclear, our observation suggests a role for the MEK-
MAPK regulatory network. It remains to be determined to
what extent MEK-MAPK represents a common point of
activation by agents promoting HCC cell proliferation or
whether MEK-MAPK is itself a critical element in the etiol-
ogy or pathogenesis of HCC.
The presence of highly activated MEK1/2 in high grade
HCCs suggests that MEK activation may tie into malig-
nant progression of liver cancer. In the present study, we
show that over-expression of activated MEK1 in HepG2
cells does not alter the growth rate of HepG2 cells in vitro.
However, over-expression of activated MEK1 enhances
tumor growth in vivo and confers drug resistance in vitro.
This is in agreement with early studies demonstrating that
transient expression of active MEK1 into HepG2 pre-
vented apoptosis in serum-deprived condition [25].
Because the in vitro growth rate is similar between pUSE-
transfected cells and activated MEK1-tranfected cells, sus-
ceptibility to apoptosis and low basal MAPK phosphoryla-
tion may explain in part by the slower growth of the
mock-transfected cells than activated MEK1-transfected
cells in SCID mice. We also noticed that both HepG2-
mock and HepG2-MEK1-transfected cells grew slowly for
the first 40 days in SCID mice, then HepG2-MEK1 tumors
grew faster. The long latent period in tumors expressing an
Induction of apoptosis by U0126 treatment in HepG2 cells Figure 7
Induction of apoptosis by U0126 treatment in HepG2 cells. HepG2 cells were grown and treated with either 0.1% 
DMSO (A) or 2 (B), 4 (C) and 6 (D) µM of U0126 in PSF medium for 48 h. Apoptotic cells were determined by TUNEL assay 
as described under Experimental Procedures. Apoptotic cells in 0.1% DMSO and U0126-treated samples were visualized under 
a fluorescent microscope. Representative samples are shown. Original magnification, ×200.
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Effects of MEK1/2 inhibitor U0126 on MAPK, phospho-MAPK (Thr202/Tyr204), cytochrome c release, and cleavage of caspase  3, caspase 7 and PARP in HepG2 cells Figure 8
Effects of MEK1/2 inhibitor U0126 on MAPK, phospho-MAPK (Thr202/Tyr204), cytochrome c release, and 
cleavage of caspase 3, caspase 7 and PARP in HepG2 cells. HepG2 cells were cultured as described under Experimen-
tal Procedures. Cells were incubated with PSF medium containing 0.1% DMSO or indicated concentrations of U0126 for 24 h 
or 48 h. Total cell lysate (for detection of cleaved caspase 3, cleaved caspase 7, cleaved PARP, and α-tubulin) or mitochondria 
free cytosol (for detection of cytochrome c) was prepared for Western blot analysis as described under Experimental Proce-
dures (A). Blots containing cell lysate were incubated with mouse anti-α-tubulin, mouse anti-MAPK, mouse anti-phospho-
MAPK (Thr202/Tyr204), rabbit anti-caspase 3, rabbit anti-cleaved caspase 7, rabbit anti-cleaved PARP antibodies. Blots contain-
ing mitochondria free cytosol were blotted with mouse anti-cytochrome c antibody. All the antibodies were used at a final con-
centration of 1 µg per ml. Apoptotic cells were determined by TUNEL assay 48 h post-UO126 treatment as described under 
Experimental Procedures. Apoptotic cells were expressed as a percentage of total cells counted (B). Representative samples 
are shown.
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Western blot analysis for levels of HA-MEK1 and phosphorylated MAPK and in vitro growth of transfectant clones Figure 9
Western blot analysis for levels of HA-MEK1 and phosphorylated MAPK and in vitro growth of transfectant 
clones. For detection of HA-MEK1 and phosphorylated MAPK, mock-transfectant (pUSE-9 and pUSE-12) and activated MEK1-
transfectant (H-MEK1-5, H-MEK1-15, H-MEK1-16 and H-MEK1-17) clones were grown and total cell lysate was prepared for 
Western blot analysis as described under Experimental Procedures. Blots were incubated with mouse anti-α-tubulin (A), rab-
bit anti-HA-MEK1 (B), mouse anti-MAPK (C), mouse anti-phospho-MAPK (Thr202/Tyr204) antibodies (D). All the antibodies 
were used at a final concentration of 1 µg per ml. For proliferation study, pUSE-9, pUSE-12, H-MEK1-15, H-MEK1-17 clones 
were seeded at a density of 2.5 × 104 cells per well in 24-well plates containing MEM supplemented with 10% fetal calf serum. 
(E) Cell number was counted daily by hemocytometer for 5 days and is plotted against number of days. Means were deter-
mined from quadruplicate wells and in no case did standard deviation exceed 15% of the mean value.
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active MEK1 may reflect a need of MEK1-expressing cells
to generate neovascularization or may be due to low basal
level of MAPK phosphorylation and weak induction that
active MEK1 induces.
In the present study, the more focal pattern of MEK-MAPK
observed in HCC nodules may reflect local autocrine/
paracrine signalling. It has been observed that paclitaxel
[40] or cisplatin [41] preferentially induced phosphoryla-
tion of p42 MAPK (ERK2) while phosphorylation of p44
MAPK was found during EGF- [42], PDGF- [29] and ara-
chidonic acid- [43] induced MAPK activation. Thus, the
widespread activation of MEK1/2 and phosphorylation of
p44 MAPK (ERK1) observed in HCCs could reflect consti-
tutive activation mediated by absence of growth inhibitor
[10] or over-expression of ras  [44], IGF-II [10], TGF-α
[45], HGF, c-met [46], and Shc [47]. Activation of MEK-
MAPK by autocrine/paracrine growth factors may help the
cells to survive even in the presence of limited nutrients
and to increase the secretion of angiogenic factors from
the tumor cells [48,49]In vivo, these angiogenic factors
then stimulate neovascularization, which is essential for
growth, survival, invasion and metastasis of liver cancer
cells.
In the present study, activated MAPK is predominantly
localized in the cytoplasm. It has been reported that
MAPK has cytoplasmic substrate in addition to the better-
characterized nuclear transcription factors [50,51]. Poten-
tial cytoplasmic substrates of MAPK include cytoskeletal
elements and regulatory enzymes, including microtubule-
associated proteins and myosin light chain kinase. [52,53]
Effects of MEK1/2 inhibitor U0126 on MAPK, phospho-MAPK (Thr202/Tyr204), and cleavage of caspase 3, caspase 7 and PARP  in pUSE-9 and H-MEK1-15 clones Figure 10
Effects of MEK1/2 inhibitor U0126 on MAPK, phospho-MAPK (Thr202/Tyr204), and cleavage of caspase 3, cas-
pase 7 and PARP in pUSE-9 and H-MEK1-15 clones. pUSE-9 and H-MEK1-15 cells were cultured as described under 
Experimental Procedures. Cells were incubated with PSF medium containing 0.1% DMSO or indicated concentrations of 
U0126 for 24 h. Total cell lysate was prepared for Western blot analysis as described under Experimental Procedures. Blots 
containing total cell lysate were incubated with mouse anti-α-tubulin (A), mouse anti-MAPK (B), mouse anti-phospho-MAPK 
(Thr202/Tyr204) (C), rabbit anti-caspase 3 (D), rabbit anti-cleaved caspase 7 (E), rabbit anti-cleaved PARP (F) antibodies. All 
the antibodies were used at a final concentration of 1 µg per ml. Representative blots are shown.
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Thus, our observation of significant cytoplasmic activated
MAPK in neoplastic cells suggests possible nontranscrip-
tional roles, such as the regulation of cytoarchitecture and
cell motility.
In the present study we are unable to co-localize activated
MAPK and MEK1/2. While phosphorylated MEK1/2 was
localized in mitotic cells (those with nuclear phosphor-
ylated MEK1/2 immunolabelling), phosphorylated
MAPK is found in every cell in the tumor nodule. Further-
more, activated MAPK is detected only in 69% (32 of 46)
of HCCs examined, while activated MEK1/2 is in 100% of
tumors. This observation is consistent with a previous
report [54] showing absent or diminished MAPK phos-
phorylation in mitotic tumor cells. It is also possible that
changes in MAPK phosphorylation are rapid. The time
from the tumor removal to the time when the tumor is
frozen or fixed may have been too long. This may explain
our failure to co-localize activated MAPK in certain tumor
samples.
Although it is well documented that apoptosis is also reg-
ulated by the Bcl-2 family of proteins [55], we do not
detect any significant changes in the levels of Bax, Bad,
Bcl-2 and Bcl-xL followed by U0126 treatment (data not
shown). Previous studies have shown that p90Rsk is acti-
vated by the MEK-MAPK [56-60]. Activated p90Rsk can
phosphorylate Bad and prevent its proapoptotic activity
In vivo growth of activated MEK1 tranfected cells Figure 11
In vivo growth of activated MEK1 tranfected cells. Mock transfected (pUSE-9 and pUSE-12) and activated MEK1 (H-
MEK1-15 and H-MEK1-17) clones were subcutaneously injected on both flanks of male SCID mice as described under Experi-
mental Procedures. Tumor growth was measured and calculated as described under Experimental Procedures. Tumor volume 
at a given time for mock transfected clones and activated MEK1-transfected clones is plotted and shown. Differences in tumor 
volume between mock-transfected and activated MEK1-transfected clones were statistically significant at p < 0.01 as analyzed 
by ANOVA test.
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Immunostaining of Ki-67 in HepG2-mock (pUSE-9 and pUSE-12) and HepG2-MEK1 (H-MEK1-15 and H-MEK1-17) tumors Figure 12
Immunostaining of Ki-67 in HepG2-mock (pUSE-9 and pUSE-12) and HepG2-MEK1 (H-MEK1-15 and H-MEK1-
17) tumors. pUSE-9, pUSE-12 H-MEK1-15 and H-MEK1-17 clones were subcutaneously injected on both flanks of male SCID 
mice as described under Experimental Procedures. Tumors were harvested, fixed, paraffin embedded and immunohistochemi-
cal analysis was performed as described under Experimental Procedures. The sections were stained with mouse anti-Ki-67 
antibody (A). For each clone, 500 cells were counted in randomly chosen fields at 400 × magnification. The Ki-67 labelling 
index was expressed as the number of clearly labelled Ki-67 reactive nuclei in 500 cells counted (B). Differences in Ki-67 label-
ling index between HepG2-mock and HepG2-MEK1-tumours were statistically significant at p < 0.05 as analyzed by ANOVA 
test. Original magnification × 400.
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[61]. Furthermore, blocking p90Rsk activity by over-
expression of a catalytically inactive form of p90Rsk
enhanced Fas-mediated cell death [61]. Using anti-phos-
pho-specific Bad (Ser122) and Bad (Ser136) antibodies,
we observed that blocking MEK1/2 activity did not alter
the levels of Bad phosphorylation at Serine 112 and Serine
136 (data not shown). Therefore, it is unlikely that
alterations of Bcl-2 family of proteins or phosphorylation
of Bad are responsible for apoptosis seen in HepG2 and
Hep3B cells following U0126 treatment.
Although activated Akt-1 exerts an anti-apoptotic effect
against various stimuli [62] and confers resistance to
chemotherapeutic drugs [63], blocking the phosphoryla-
tion of Akt by LY294002 only causes mild apoptosis in
HepG2 and Hep3B cells. The results indicate that at least
under our experimental conditions, Akt activity does not
play a significant role in the survival of liver cancer cells in
serum-deprived condition. In vivo the tumor cells may
depend on more than one survival pathway. Interaction
with extracellular matrices in vivo allows the tumor cells to
activate other survival pathways such as fibronectin-FAK-
JNK [64], which also plays an important role in the sur-
vival of tumor cells.
In mammalian cells, there are at least two pathways
involved in apoptosis. One involves caspase 8, which is
recruited by the adapter molecule Fas/APO-1 associated
death domain protein to death receptors upon extracellu-
lar ligand binding [65,66]. The other involves cytochrome
c release-dependent activation of caspase 9 through Apaf-
1 [37,38]. We did not observe any changes in either Fas or
FasL expression in U0126-treated HepG2 and Hep3B
cells. We did, however, observe an increase in cleaved
caspase 3, cleaved caspase 7, cleaved PARP and cytoplas-
mic cytochrome c in U0126 treated cells indicating that
cytochrome c release following U0126 treatment may be
responsible for the activation of both caspase 7 and 3
which, in turn, induce apoptosis. This hypothesis is sup-
ported by Germain et al. [67] who demonstrate that
activation of caspase 7 is involved in cleavage of PARP and
apoptosis.
In summary, we have shown that high expression levels of
MAPK, phosphorylated MAPK and phosphorylated
MEK1/2 are found in tumors of HCC patients. Treatment
of liver cancer cells with MEK inhibitor U0126, leads to
growth inhibition and apoptosis in vitro. Over-expression
of activated MEK1 enhances tumor growth in vivo and
confers resistance to U0126-induced apoptosis. Our data
point to the role(s) of activated MEK1/2 and MAPK in
hepatocarcinoma cell survival and tumor growth, and the
potential use of MEK1/2 inhibitors in treatment of HCC.
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